ABSI

Absci Corporation (ABSI)
Healthcare • Biotechnology • $8.30 • MCap: 1,405,175,808 🌐
https://www.absci.com • Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Buy Decision Core
Total Score
29
Business Quality
1
Financial Strength
9
Growth Outlook
1
Momentum
6
Price Action
Current
8.30
52W High
11.62
52W Low
2.30
Above 50DMA
7.65 (8.41%)
Above 200DMA
4.44 (86.92%)
Relative Strength
Relative Strength
1.42
RS 3M
1.57
RS 6M
1.48
RS 9M
1.13
RS 12M
1.36
Fundamentals
Revenue Growth
-0.82%
Earnings Growth
0%
ROE
-0.64%
ROA
-0.37%
Valuation
PE (Fwd)
-13.32
PEG
0
P/B
7.49
Upside
66.10%
Risk
Beta
2.33
Short %
0.27
Risk Score
8.00
Analyst
Rating
strong_buy
Target
13.78
Beta
2.33
Analysts
0
Total Score
29
Upside
66.10%
Relative Strength
1.42
Beta
2.33
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Trading above 50 DMA
  • Trading above 200 DMA
  • Analyst upside exceeds 15%
Key Risks
  • Revenue growth is negative
  • Negative ROE
  • High volatility (Beta > 1.5)
Score Breakdown
Business
1
Financial
9
Growth
1
Valuation
8
Risk
0
Momentum
6
Technical
52W High: 11.62
52W Low: 2.30
Above 50DMA: 8.41%
Above 200DMA: 86.92%
Valuation
Forward PE: -13.32
PEG: 0
P/B: 7.49
Upside: 66.10%
Risk
Beta: 2.33
Short Float: 0.27%
ROE: -0.64%
ROA: -0.37%